[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604319":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":37,"collaborators":26,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":26,"eligibilityCriteria":46,"healthyVolunteers":43,"sex":47,"minAge":48,"maxAge":26,"enrollmentInfo":49,"targetDuration":26,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":60,"whyStopped":26,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":26},{"fullName":5,"class":6},"Fayoum University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1","ACTIVE_COMPARATOR","Conventional Therapy",[13],"Drug: Propranolol 80 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Group 2","PLACEBO_COMPARATOR","Nutraceutical Therapy",[19],"Drug: Magnesium 400Mg",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Propranolol 80 mg","Propranolol 40-80 mg\u002Fday",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Magnesium 400Mg","Magnesium 400 mg daily",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Marwa Kamal Tolba, Associate professor","CONTACT","01067789982","mka05@fayoum.edu.eg",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Marwa Ahmed Kamal Tolba","Associate professor clinical pharmacy department -faculty of pharmacy- fayoum university","100604319","phase-3-comparative-study-of-nutraceuticals-vs-conventional-prophylactic-therapy-in-the-management-of-migraine-100604319",false,"NCT07147972","Comparative Study of Nutraceuticals vs. Conventional Prophylactic Therapy in the Management of Migraine","Inclusion Criteria:\n\n* Adults aged 18-60 years\n\n  * \\- Diagnosed with episodic migraine (ICHD-3 criteria)\n  * \\- ≥4 migraine attacks\u002Fmonth for the past 3 months\n  * \\- Willing to provide informed consent\n\nExclusion Criteria:\n\n* • - Chronic migraine (\\>15 headache days\u002Fmonth)\n\n  * \\- Use of other prophylactic treatments in past month\n  * \\- History of secondary headaches\n  * \\- Pregnancy or breastfeeding\n  * \\- Significant renal, hepatic, or cardiac disease","ALL","18 Years",{"count":50,"type":51},100,"ESTIMATED","INTERVENTIONAL",[54],"PHASE3","Migraine is a common disabling neurological condition that significantly affects quality of life. While traditional prophylactic treatments (e.g., beta-blockers, antiepileptics) are effective, they may be associated with side effects leading to poor adherence. Recent evidence suggests that nutraceuticals like magnesium, riboflavin, and coenzyme Q10 may provide a safer alternative. This study aims to compare the efficacy and tolerability of these two approaches.",[57,58],"Migraine","Nutraceuticals",[57,58],"NOT_YET_RECRUITING","2025-08-27",{"date":63,"type":64},"2025-08-29","ACTUAL",{"date":66,"type":51},"2025-08-20",{"date":68,"type":51},"2026-02-01",{"name":5,"class":6}]